PROG

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes.